Balaxi Pharma

Why is Balaxi Pharmaceuticals Ltd falling/rising?

As of 07-Jul, Balaxi Pharmaceuticals Ltd's stock price is declining at 23.85, down -0.62%, due to significant underperformance over the past year and deteriorating financial health, including a -93.92% drop in profit after tax and a projected -27.00% decline in operating profits. The stock's high valuation and low liquidity further exacerbate its poor performance.

As of 07-Jul, Balaxi Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 23.85, which reflects a change of -0.15 or -0.62%. This downward movement can be attributed to several factors highlighted in the provided data. <BR><BR>Firstly, the stock has consistently underperformed against the benchmark, with a significant drop of -51.30% over the past year, while the BSE500 index has only decreased by -4.17%. This trend of underperformance extends over the last three years, where the stock has generated negative returns and has not matched the performance of its peers.<BR><BR>Moreover, the company's financial health appears to be deteriorating, as indicated by a -93.92% growth in profit after tax over the last nine months and a -7.29% decline in net sales for the quarter. The operating profits are also projected to decline at a compound annual growth rate (CAGR) of -27.00%, suggesting weak long-term fundamental strength. <BR><BR>Additionally, the stock is trading at a premium compared to its peers, with a price-to-book value of 0.5, which is considered expensive given its low return on equity (ROE) of 0.6. The liquidity of the stock is also a concern, as it is only liquid enough for a trade size of Rs 0 crore based on 2% of the five-day average traded value.<BR><BR>While there has been a slight increase in institutional investor participation, with a 0.79% rise in their stake, this has not been sufficient to counterbalance the negative financial indicators and the stock's overall poor performance. Thus, the combination of weak financial results, high valuation, and consistent underperformance against benchmarks contributes to the falling stock price of Balaxi Pharmaceuticals Ltd.

Which are the latest news on Balaxi Pharma?

How big is Balaxi Pharma?

As of 10th June, Balaxi Pharmaceuticals Ltd has a market capitalization of 133.00 Cr, with recent net sales of 270.17 Cr and a net profit of 1.42 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Balaxi Pharmaceuticals Ltd has a market capitalization of 133.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 270.17 Cr, while the sum of Net Profit for the same period is 1.42 Cr.<BR><BR>Balance Sheet Snapshot: The latest annual period reported is March 2025, with Shareholder's Funds amounting to 231.74 Cr and Total Assets of 310.34 Cr.

Who are in the management team of Balaxi Pharma?

The management team of Balaxi Pharma includes Ashish Maheshwari (Chairman/Executive Director), Minoshi Maheshwari (Non Executive Director), and five Independent Non Executive Directors: Kunal M Bhakta, Gandhi Gamji, M. Srinivas Rao, and Purnima Singh Kamble.

The management team of Balaxi Pharma includes the following members:<BR><BR>1. **Ashish Maheshwari** - Chairman / Executive Director<BR>2. **Minoshi Maheshwari** - Non Executive Director<BR>3. **Kunal M Bhakta** - Independent Non Executive Director<BR>4. **Gandhi Gamji** - Independent Non Executive Director<BR>5. **M. Srinivas Rao** - Independent Non Executive Director<BR>6. **Purnima Singh Kamble** - Independent Non Executive Director<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

Who are the peers of the Balaxi Pharma?

Balaxi Pharma's peers include Alpa Laboratorie, Krebs Biochem, Bal Pharma, Sotac Pharma, Lactose (India), Tyche Industries, Smruthi Organic, Godavari Drugs, and Concord Drugs. Balaxi Pharma has a low 1-year return of -56.08%, while Lactose (India) leads with a return of 0.00%.

Peers: The peers of Balaxi Pharma are Alpa Laboratorie, Krebs Biochem, Bal Pharma, Sotac Pharma, Lactose (India), Tyche Industries, Smruthi Organic, Godavari Drugs, and Concord Drugs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Alpa Laboratorie and Denis Chem Lab, while Average management risk is found at Bal Pharma, Balaxi Pharma, Smruthi Organic, Godavari Drugs, and Tyche Industries. Below Average management risk is noted at Sotac Pharma, Lactose (India), and Concord Drugs. Growth is Excellent at Lactose (India), Below Average at Alpa Laboratorie, Bal Pharma, Balaxi Pharma, Smruthi Organic, Godavari Drugs, and Tyche Industries, and does not qualify for Krebs Biochem. Capital Structure is Excellent at Alpa Laboratorie and Balaxi Pharma, Good at Smruthi Organic, and Below Average at Krebs Biochem, Bal Pharma, Sotac Pharma, Lactose (India), Tyche Industries, Godavari Drugs, and Concord Drugs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Lactose (India) at 0.00%, while Balaxi Pharma has the lowest at -56.08%, indicating a significantly poorer performance compared to its peers. Additionally, Alpa Laboratorie, Krebs Biochem, Bal Pharma, Sotac Pharma, and Godavari Drugs all have negative six-month returns.

What does Balaxi Pharma do?

Balaxi Pharmaceuticals Ltd, a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reported net sales of 71 Cr and a net profit of 1 Cr for March 2026. The company, originally incorporated in 1942, focuses on pharmaceutical products and has a market cap of INR 133 Cr.

Overview: <BR>Balaxi Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated in 1942 under the name 'The Anandam Rubber Company Limited' and changed its name to 'Balaxi Ventures Limited' in 2017. The latest quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 71 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 1 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 133 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 95.00 <BR>Industry P/E: 20 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.23 <BR>Return on Equity: 0.57% <BR>Price to Book: 0.54<BR><BR>Contact Details: <BR>Address: 41/298-D2 2nd Flr Saniya Plaza, Mahakavi Bharatiyar Road Cochin Kerala : 682035 <BR>Tel: 91-484-4032952/6596725 <BR>Email: secretarial@anandamrubberco.com <BR>Website: http://www.balaxipharma.in

Should I buy, sell or hold Balaxi Pharmaceuticals Ltd?

Are Balaxi Pharmaceuticals Ltd latest results good or bad?

Balaxi Pharmaceuticals Ltd's latest Q4 FY26 results are concerning, showing a 92.94% decline in net profit and a 7.29% drop in revenue year-on-year. The operating margin has plummeted to 0.17%, indicating significant operational challenges and raising doubts about the company's profitability and sustainability.

Balaxi Pharmaceuticals Ltd's latest results for Q4 FY26 are concerning and indicate a significant decline in financial performance. The company reported a net profit of ₹0.61 crore, which represents a staggering 92.94% decrease year-on-year. Revenue also fell by 7.29% compared to the same quarter last year, totaling ₹70.71 crore. <BR><BR>The operating margin has collapsed to just 0.17%, down from 16.47% a year earlier, reflecting severe operational challenges. This drastic margin compression suggests that the company is struggling to maintain profitability in its core pharmaceutical operations. Additionally, the return on equity (ROE) has dropped to 6.09% from an average of 25.08%, indicating a significant decline in capital efficiency.<BR><BR>Overall, these results highlight a troubling trend of declining revenues and profitability, raising serious questions about the sustainability of Balaxi's business model in a competitive market. The financial metrics suggest that the company is facing critical challenges that could hinder its recovery in the near term.

Is Balaxi Pharma overvalued or undervalued?

As of November 27, 2025, Balaxi Pharma is considered very attractive and undervalued with a PE ratio of 14.36, significantly lower than its peers like Bajaj Finance and Bajaj Finserv, despite a 53.22% decline in stock performance over the past year.

As of 27 November 2025, Balaxi Pharma's valuation grade has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued, with a PE ratio of 14.36, an EV to EBIT of 11.30, and an EV to EBITDA of 10.33. These ratios suggest that Balaxi Pharma is trading at a lower valuation compared to its peers, particularly when compared to Bajaj Finance, which has a PE ratio of 35.15, and Bajaj Finserv, with a PE ratio of 34.78.<BR><BR>In the context of its industry, Balaxi Pharma's Price to Book Value stands at 0.87, which further reinforces its undervaluation relative to competitors like Life Insurance, which has a PE ratio of 11.14 and an EV to EBITDA of 9.18. Despite recent stock performance showing a decline of 53.22% over the past year compared to a 7.99% increase in the Sensex, the current valuation metrics position Balaxi Pharma as an attractive investment opportunity moving forward.

How has been the historical performance of Balaxi Pharma?

Balaxi Pharma's historical performance shows fluctuating financial metrics, with net sales increasing to 292.56 Cr in March 2025 from 241.29 Cr in March 2024, but declining from 336.43 Cr in March 2023. Profit after tax also decreased to 25.07 Cr in March 2025, down from 35.91 Cr in March 2024 and 45.96 Cr in March 2023.

Answer:<BR>The historical performance of Balaxi Pharma shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Balaxi Pharma's net sales reached 292.56 Cr in March 2025, an increase from 241.29 Cr in March 2024, but a decline from 336.43 Cr in March 2023. Total operating income mirrored this trend, with 292.56 Cr in March 2025 compared to 241.29 Cr in March 2024 and 336.43 Cr in March 2023. The company's total expenditure, excluding depreciation, was 255.35 Cr in March 2025, rising from 194.56 Cr in March 2024 but down from 279.90 Cr in March 2023. Operating profit (PBDIT) decreased to 33.49 Cr in March 2025 from 44.08 Cr in March 2024 and 59.17 Cr in March 2023. Profit before tax also declined to 28.67 Cr in March 2025 from 40.31 Cr in March 2024 and 56.92 Cr in March 2023, leading to a profit after tax of 25.07 Cr in March 2025, down from 35.91 Cr in March 2024 and 45.96 Cr in March 2023. The company's total assets increased to 310.34 Cr in March 2025 from 258.34 Cr in March 2024, while total liabilities also rose to 310.34 Cr in March 2025 from 258.34 Cr in March 2024. Cash flow from operating activities showed a negative trend, with -35.00 Cr in March 2025 compared to 4.00 Cr in March 2024, while cash and cash equivalents decreased to 39.00 Cr in March 2025 from 62.00 Cr in March 2024.

How has been the historical performance of Balaxi Pharma?

Balaxi Pharma's historical performance shows fluctuating net sales and profits, with net sales increasing to 292.56 Cr in March 2025 but profits declining, resulting in a profit after tax of 25.07 Cr. The company faces challenges in cash generation, as indicated by negative cash flow from operating activities.

Answer:<BR>The historical performance of Balaxi Pharma shows a fluctuating trend in net sales and profits over the years, with a notable increase in recent periods.<BR><BR>Breakdown:<BR>Balaxi Pharma's net sales reached 292.56 Cr in March 2025, up from 241.29 Cr in March 2024, but down from 336.43 Cr in March 2023. The total operating income followed a similar pattern, peaking at 336.43 Cr in March 2023 before declining to 292.56 Cr in March 2025. The company's total expenditure, excluding depreciation, was 255.35 Cr in March 2025, which was an increase from 194.56 Cr in March 2024 but lower than 279.90 Cr in March 2023. Operating profit (PBDIT) decreased to 33.49 Cr in March 2025 from 44.08 Cr in March 2024, reflecting a declining operating profit margin of 12.72%. Profit before tax also saw a decline to 28.67 Cr in March 2025 from 40.31 Cr in March 2024, leading to a profit after tax of 25.07 Cr in March 2025, down from 35.91 Cr in March 2024. The company's total assets increased to 310.34 Cr in March 2025, up from 258.34 Cr in March 2024, while total liabilities also rose to 310.34 Cr from 258.34 Cr. Cash flow from operating activities turned negative at -35.00 Cr in March 2025, contrasting with a positive cash flow of 4.00 Cr in March 2024, indicating challenges in cash generation. Overall, Balaxi Pharma's financial performance reflects volatility with a recent trend of declining profits despite increased sales.

Who are the top shareholders of the Balaxi Pharma?

The top shareholders of Balaxi Pharma include Balaxi Overseas Private Limited with 63.4%, foreign institutional investors holding 16.02%, and Unico Global Opportunities Fund Limited as the largest public shareholder at 8.29%. Individual investors own 9.82%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Balaxi Pharma include the promoters, with Balaxi Overseas Private Limited holding the largest share at 63.4%. Additionally, foreign institutional investors (FIIs) collectively hold 16.02%, with three FIIs involved. The highest public shareholder is Unico Global Opportunities Fund Limited, which owns 8.29%. Individual investors account for 9.82% of the company's shares. There are no pledged promoter holdings, and no mutual funds currently hold shares in the company.

What is the technical trend for Balaxi Pharma?

As of April 21, 2025, Balaxi Pharma's technical trend has shifted to a moderate bearish stance, driven by bearish MACD, moving averages, and KST indicators, despite some divergence in the RSI and mildly bearish Bollinger Bands.

As of 21 April 2025, the technical trend for Balaxi Pharma has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on both weekly and monthly time frames, bearish moving averages on the daily chart, and a bearish KST on both weekly and monthly time frames. The RSI shows no signal on the weekly but is bullish on the monthly, indicating some divergence. Bollinger Bands are mildly bearish on both weekly and monthly charts, while the Dow Theory indicates a mildly bearish trend on the weekly and no trend on the monthly. Overall, the bearish signals dominate the current technical outlook.

When is the next results date for Balaxi Pharma?

No Upcoming Board Meetings

Has Balaxi Pharma declared dividend?

Balaxi Pharmaceuticals Ltd has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of July 1, 2022. Despite this, the company has experienced significant volatility, showing negative total returns in shorter periods, while the 5-year period reflects a positive return of 138.34%.

Balaxi Pharmaceuticals Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 01 Jul 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -38.66%, the dividend return was 0%, resulting in a total return of -38.66%.<BR><BR>For the 1-year period, the price return was -51.55%, the dividend return was 0%, leading to a total return of -51.55%.<BR><BR>Over the 2-year period, the price return was -51.61%, with a dividend return of 0%, culminating in a total return of -51.61%.<BR><BR>In the 3-year period, the price return was -37.85%, the dividend return was 0.68%, resulting in a total return of -37.17%.<BR><BR>For the 4-year period, the price return was -57.93%, the dividend return was 0.43%, leading to a total return of -57.5%.<BR><BR>In the 5-year period, the price return was 136.37%, with a dividend return of 1.97%, culminating in a total return of 138.34%.<BR><BR>Overall, Balaxi Pharmaceuticals Ltd has declared a dividend, but the total returns over the various periods indicate significant volatility, with negative returns dominating in the shorter time frames, while the 5-year period shows a substantial positive return.